US3836639A - Use of aromatic glyoxals,their hydrates and bisulfite addition salts in reducing blood platelet aggregation - Google Patents

Use of aromatic glyoxals,their hydrates and bisulfite addition salts in reducing blood platelet aggregation Download PDF

Info

Publication number
US3836639A
US3836639A US00398898A US39889873A US3836639A US 3836639 A US3836639 A US 3836639A US 00398898 A US00398898 A US 00398898A US 39889873 A US39889873 A US 39889873A US 3836639 A US3836639 A US 3836639A
Authority
US
United States
Prior art keywords
platelet aggregation
glyoxal
addition salts
hydrates
blood platelet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00398898A
Inventor
D Teler
R Fenichel
C Guinosso
S Bell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Priority to US00398898A priority Critical patent/US3836639A/en
Application granted granted Critical
Publication of US3836639A publication Critical patent/US3836639A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes

Definitions

  • the phenyl glyoxals of this invention are known compounds, with the exception of 2,o-dichlorophenylglyoxal, the preparation of which is presented infra. J. Am. Chem. Soc., 79, 1687 (1957) and Biochem. Z., 279, 459 (1935).
  • the bisulfite addition products of the compounds used in the instant invention are known with the exception of the p-tolyl glyoxal derivative.
  • a new use'for various aromatic glyoxal derivatives which comprises a process for inhibiting blood platelet aggregation by adding to said platelets in vitro or in viva an effective amount of a'compound selected from the group consisting of lphenyl glyoxal, p-tolyl glyoxal, p-methoxyphenyl glyoxal, p-chlorophenyl glyoxal, 2,6-dichlorophenyl glyoxal, and the hydrates and bisulfite addition salts thereof.
  • the effective amount of the active compounds employed in vitro may be readily determined from the data provided infra.
  • the effective amount is a prophylactic amount based upon the requirement ofthe individual patient.
  • the anti-platelet aggregation agents prevent the breakdown of blood platelets and the. possible consequential thrombosis resulting from such breakdown.
  • the compounds employed in this invention may be administered orally or intramuscularly, in the case of an emergency, in a daily dose up to 600 milligramsper a 7.0 kilogram patient.
  • the compounds used inthe present invention may be administered in multiple dose form up to and including 600 milligrams per day, as prescribed by a physician, taking into consideration the'a ge, general physical condition, weight, and medical historyofth'e patient being treated.
  • the process of this invention is useful in the treatment of the arteriosclerotic process which may begin in a thrombus formation via blood platelet aggregation or clotting.
  • the compounds being tested were incorporated in identical formulations and the concentration afiecting 50 percent inhibition of the adenosine diphosphate activity was determined by comparison with a standard curve.
  • the compounds employed in the process of this invention inhibited blood platelet aggregation at concentrations as low as about 0.03 millimolar, while increased activity occurred with increased concentration.
  • the compounds were tested for their capacity to inhibit adenosine diphosphate (ADP) induced reduction of circulating blood platelets in control and treated groups of male Sprague Dawley rats.
  • a control cardiac blood sample was taken and each compound tested was given to the experimental group at a starting dose of mg./kg. or lower depending on the nature of the compound under test. After 30 minutes 15 rug/kg. of ADP was injected into the leg vein. Cardiac blood samples were taken at 20, 4t) and 60 seconds. The control group was given only ADP. Platelet counts were made on all blood samples with a Coulter Counter, the results plotted, and the percentage of inhibition determined. Active compounds were run at lower concentrations, and the results are expressed as the lowest dose showing significant inhibition of the ADP effect.
  • ADP adenosine diphosphate
  • the biological activity of the glyoxal derivatives employed in the process of this invention are presented in the following table in which the concentration of the specific compound employed which gives a 50 percent inhibition of adenosine diphosphate induced blood platelet aggregation is presented.
  • the first number appearing is that obtained from studies with platelet rich plasma obtained from normal fasted male rats
  • the second number presented is the data obtained from treatment of human platelet rich plasma
  • the third set of data represents the results of in vivo experiments expressed in terms of milligrams per kilogram host body weight. It should be noted that the indication of slight activity or no significant activity is not an indication of absence of activity in human blood platelet aggregation inhibition.
  • the purpose for performing the more stringent tests on live rats was to establish additional information relative to the degree of effective activity of the compounds being tested, rather than to establish the fact of activity in the human, which is shown by the studies on human platelet rich plasma.
  • the in vivo data must be interpreted from the standpoint of demonstrating the most active member(s) of a family of compounds being tested, rather than as a definitive test directly correlated with the human upon which the absence of activity of a compound can be predicated.
  • the process for preventing blood platelet aggregation presented in this application embraces the use of the disclosed compounds in treating human patients on a prophylactic basis Where the tendency for blood platelet aggregation has been initiated by a disease, or the prevention of platelet aggregation in storage for subsequent use in the treatment of patients suffering from leukemia, thrombocytopenia, and similar maladies.
  • the glyoxal derivatives employed in this invention preserve blood platelets, preventing stickiness or aggregation, for subsequent administration to the patient.
  • the anti-platelet aggregation agents of this invention may be used by themselves for treatment of platelets prior to storage, or conventional formulations incorporating the active compounds may be formed for ease in dispensation, and in the case of formulations for in vivo treatment of Warm-blooded animals, conventional adjuvants known to the pharmaceutical chemist may be added to the active ingredient in appropriate measure.
  • tablets may be prepared to contain approximately 80 parts sucrose, 13 parts starch, 6 parts magnesium stearate and dose multiples of active ingredient ranging from ca. 50, 100, 200 to 250 parts.
  • injectible solutions are prepared by dissolving the active compound in the desired concentration of water or alcoholic vehicle with or without buffer, stabilizer, etc.
  • a process for inhibiting blood platelet aggregation which comprises adding to said blood platelets an effective amount of a compound selected from the group consisting of phenyl glyoxal, p-tolyl glyoxal, p-methoxyphenyl glyoxal, p-chlorophenyl glyoxal, 2,6-dichlorophenyl glyoxal and the hydrates and bisulfite addition salts thereof.
  • said effective amount is a prophylactic amount incrementally administered at a dosage up to and including 600 mi1li grams per day, per a 70 kilogram patient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

CERTAIN AROMATIC GLYOXAL DERIVATIVES, THEIR HYDRATES AND BISULFITE ADDITION SALTS ARE USEFUL ANTI-BLOOD PLATELET AGGREGATION AGENTS IN VITRO AND IN VIVO.

Description

United States Patent O US. Cl. 424-101 9 Claims ABSTRACT OF THE DISCLOSURE Certain aromatic glyoxal derivatives, their hydrates andbisulfite addition salts are useful anti-blood platelet aggregation agents in vitro and in vivo.
BACKGROUND OF THE INVENTION The phenyl glyoxals of this invention are known compounds, with the exception of 2,o-dichlorophenylglyoxal, the preparation of which is presented infra. J. Am. Chem. Soc., 79, 1687 (1957) and Biochem. Z., 279, 459 (1935). Similarly, the bisulfite addition products of the compounds used in the instant invention are known with the exception of the p-tolyl glyoxal derivative.
DESCRIPTION OF THE INVENTION In accordance with this invention there is provided a new use'for various aromatic glyoxal derivatives which comprises a process for inhibiting blood platelet aggregation by adding to said platelets in vitro or in viva an effective amount of a'compound selected from the group consisting of lphenyl glyoxal, p-tolyl glyoxal, p-methoxyphenyl glyoxal, p-chlorophenyl glyoxal, 2,6-dichlorophenyl glyoxal, and the hydrates and bisulfite addition salts thereof. The effective amount of the active compounds employed in vitro may be readily determined from the data provided infra. For in vivo administration the effective amount is a prophylactic amount based upon the requirement ofthe individual patient.
In the prophylactic treatment of patients subject to potential blood platelet aggregation such as in the case of patients suffering from diabetes, hypertension, or presenting a history of myocardial infarction or in the case of cerebral vascular accidents etc., the anti-platelet aggregation agents prevent the breakdown of blood platelets and the. possible consequential thrombosis resulting from such breakdown. The compounds employed in this invention may be administered orally or intramuscularly, in the case of an emergency, in a daily dose up to 600 milligramsper a 7.0 kilogram patient. The compounds used inthe present invention may be administered in multiple dose form up to and including 600 milligrams per day, as prescribed by a physician, taking into consideration the'a ge, general physical condition, weight, and medical historyofth'e patient being treated. As such, the process of this invention is useful in the treatment of the arteriosclerotic process which may begin in a thrombus formation via blood platelet aggregation or clotting.
The in vitro activity of the compounds employed in the process of this invention as inhibitors of blood platelet aggregation was evaluated, essentially following the procedure of Born, G. V. R. and Cross, M. 1., J. Physiol., 168, 178-195 (1963). The in v'itro studies were made on platelet rich plasma obtained from normal fasted male 3,836,639 Patented Sept. 17, 1974 rats. Adenosine diphosphate was added to the platelet rich plasma in an amount predetermined to maximize platelet aggregation. A curve of percent light transmission at 610 millimicrons was plotted for a 7 minute period. The compounds being tested were incorporated in identical formulations and the concentration afiecting 50 percent inhibition of the adenosine diphosphate activity was determined by comparison with a standard curve. The compounds employed in the process of this invention inhibited blood platelet aggregation at concentrations as low as about 0.03 millimolar, while increased activity occurred with increased concentration.
The in vin'o studies in accordance with the preceding paragraph were repeated employing, in lieu of platelet rich plasma obtained from normal fasted rats, human platelet rich plasma. The compounds employed in the process of this invention inhibited platelet aggregation in human platelet rich plasma at concentrations as low as about 0.5 millimolar, with increased activity occurring with increase concentration.
For in vivo activity, the compounds were tested for their capacity to inhibit adenosine diphosphate (ADP) induced reduction of circulating blood platelets in control and treated groups of male Sprague Dawley rats. A control cardiac blood sample was taken and each compound tested was given to the experimental group at a starting dose of mg./kg. or lower depending on the nature of the compound under test. After 30 minutes 15 rug/kg. of ADP was injected into the leg vein. Cardiac blood samples were taken at 20, 4t) and 60 seconds. The control group was given only ADP. Platelet counts were made on all blood samples with a Coulter Counter, the results plotted, and the percentage of inhibition determined. Active compounds were run at lower concentrations, and the results are expressed as the lowest dose showing significant inhibition of the ADP effect.
The biological activity of the glyoxal derivatives employed in the process of this invention are presented in the following table in which the concentration of the specific compound employed which gives a 50 percent inhibition of adenosine diphosphate induced blood platelet aggregation is presented. The first number appearing is that obtained from studies with platelet rich plasma obtained from normal fasted male rats, the second number presented is the data obtained from treatment of human platelet rich plasma, and the third set of data represents the results of in vivo experiments expressed in terms of milligrams per kilogram host body weight. It should be noted that the indication of slight activity or no significant activity is not an indication of absence of activity in human blood platelet aggregation inhibition. In practice, the species diiference between the human and the standard test animal-the rat-is such that the rats blood platelets are considerably more resistant in vivo to adenosine diphosphate aggregation than are human platelets. Hence, the purpose for performing the more stringent tests on live rats was to establish additional information relative to the degree of effective activity of the compounds being tested, rather than to establish the fact of activity in the human, which is shown by the studies on human platelet rich plasma. Hence, the in vivo data must be interpreted from the standpoint of demonstrating the most active member(s) of a family of compounds being tested, rather than as a definitive test directly correlated with the human upon which the absence of activity of a compound can be predicated.
i ii i i 1| ([3-CH (ll-CE C H S OaNa Cl- Cl Cl CH3 (3.3X10 M) (1.4Xl- M) (1.2Xl0- M) (5Xl0- M) (1.25X' M) (7.0X10- M) 25 mgJkg 25 rug/kg. 50 n1g./kg-no significant activity 0 OH O OH O 0 ll II I! ll (i7C{ (|3CI\1 0-0 H S O Na. S O aNa l CH3 CH (1.9X10' M) (6.2X10 M) (2.2X10- M) (7.1X10 M) (1.2X10" M) (5.0X10' M) 25 IngJkg. 50 mg./kg.-slight 50 mg./kg.no
activity significant activity if i i i ii (ll-CH C-OH (J-CH S OaNa -H;O -H O I Cl 0 CH3 (2.3XlO- M) (2.3X10- M) (3.1 X10- M) (5.8X10' M) (4.9X10- M) (2.4Xl0- M) 25 rug/kg. 50 mg./kg.no
significant activity It is to be understood the process for preventing blood platelet aggregation presented in this application embraces the use of the disclosed compounds in treating human patients on a prophylactic basis Where the tendency for blood platelet aggregation has been initiated by a disease, or the prevention of platelet aggregation in storage for subsequent use in the treatment of patients suffering from leukemia, thrombocytopenia, and similar maladies. As an anti-platelet aggregation agent, the glyoxal derivatives employed in this invention preserve blood platelets, preventing stickiness or aggregation, for subsequent administration to the patient.
The anti-platelet aggregation agents of this invention may be used by themselves for treatment of platelets prior to storage, or conventional formulations incorporating the active compounds may be formed for ease in dispensation, and in the case of formulations for in vivo treatment of Warm-blooded animals, conventional adjuvants known to the pharmaceutical chemist may be added to the active ingredient in appropriate measure. For example, tablets may be prepared to contain approximately 80 parts sucrose, 13 parts starch, 6 parts magnesium stearate and dose multiples of active ingredient ranging from ca. 50, 100, 200 to 250 parts. Likewise, injectible solutions are prepared by dissolving the active compound in the desired concentration of water or alcoholic vehicle with or without buffer, stabilizer, etc.
The following preparative procedures for producing the glyoxal derivatives employed in the process of this invention are presented for the purpose of illustrating preparative techniques which may be used in the production of the known compounds employed in this invention as well as the novel derivatives thereof.
EXAMPLE 1 2,6-Dichlorophenyl glyoxal A solution of selenium dioxide (95.2 g., 0.86 moles) in dioxane (480 ml.) and water (16 ml.) is heated to 50 C.
2,6-Dichloroacetophenone [Ber, 70, 921 (1937)] (89.6 g., 0.475 moles) is added over five minutes and the mixture heated at reflux for six hours. After standing at room temperature for 72 hours the mixture is filtered and evaporated in. vacuo. Two vacuum distillations give the product, 6.0 g. of yellow liquid; b.p. 94-96 C.@0.2 mm.;
A511. 5.85, 5.90 pi;
NMR indicates ca. 10% of starting ketone in the product.
Elemental analysis for C H Cl O Calcd: C, 47.33; H, 1.99; Cl, 34.93. Found: c, 47.31; H, 2.38; (:1, 34.62.
EXAMPLE 2 Hydroxy(p-toluoyl)methanesulfonic acid sodium salt To a solution of (p-tolyl)glyoxal, hydrate [Biochem. Z., 279, 459 (1935)] (0.030 moles) in methanol (15 ml.) at room temperature is added all at once a solution of sodium bisulfite (3.15 g., 0.030 moles) in water (25 ml.). After 2 minutes the product begins to precipitate. After cooling at 0 C. for 1 hour the mixture is filtered and the precipitate recrystallized from Water/ethanol to give the colorless product; 5.8 g.; m.p. 198-205 C.
NMR has 2.10, 6.22 ppm. peaks.
Elemental analysis for C H NaO S:
Calcd: C, 42.88; H, 3.60; S, 12.71; Na, 9.11. Found: C, 42.80; H, 3.61; S, 12.96; Na, 9.22. What is claimed is:
1. A process for inhibiting blood platelet aggregationwhich comprises adding to said blood platelets an effective amount of a compound selected from the group consisting of phenyl glyoxal, p-tolyl glyoxal, p-methoxyphenyl glyoxal, p-chlorophenyl glyoxal, 2,6-dichlorophenyl glyoxal and the hydrates and bisulfite addition salts thereof.
2. The process of claim 1 in which said effective amount is a prophylactic amount incrementally administered at a dosage up to and including 600 mi1li grams per day, per a 70 kilogram patient.
3. The process of claim 1 in which said compound is administered orally.
4. The process of claim 1 in which said compound is administered intramuscularly.
5. The process of claim 1 in which said compound is phenyl glyoxal, its hyrate or bisulfite addition salts.
6. The process of claim 1 in which said compound is p-tolyl glyoxal, its hydrate or bisulfite addition salts.
7. The process of claim 1 in which said compound is p-methoxyphenyl glyoxal, its hydrate or bisulfite addi- 2,6-dichlorophenyl glyoxal, its hydrates or bisulfite addition salts.
References Cited Chem. Abst., 8th collective (1967-1971), vol. 66-75, pp. 5112s and 5113s.
SAM ROSEN, Primary Examiner US. Cl. X.R. 4243l5, 331, 333
US00398898A 1973-09-19 1973-09-19 Use of aromatic glyoxals,their hydrates and bisulfite addition salts in reducing blood platelet aggregation Expired - Lifetime US3836639A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US00398898A US3836639A (en) 1973-09-19 1973-09-19 Use of aromatic glyoxals,their hydrates and bisulfite addition salts in reducing blood platelet aggregation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US00398898A US3836639A (en) 1973-09-19 1973-09-19 Use of aromatic glyoxals,their hydrates and bisulfite addition salts in reducing blood platelet aggregation

Publications (1)

Publication Number Publication Date
US3836639A true US3836639A (en) 1974-09-17

Family

ID=23577255

Family Applications (1)

Application Number Title Priority Date Filing Date
US00398898A Expired - Lifetime US3836639A (en) 1973-09-19 1973-09-19 Use of aromatic glyoxals,their hydrates and bisulfite addition salts in reducing blood platelet aggregation

Country Status (1)

Country Link
US (1) US3836639A (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982000097A1 (en) * 1980-06-30 1982-01-21 & R Chem Inc T The use of certain sulfites or bisulfites in compositions for treating thrombotic conditions
US4327083A (en) * 1977-12-12 1982-04-27 T & R Chemicals, Inc. Treatment of hypertension with bisulfite
US4400396A (en) * 1981-06-16 1983-08-23 T & R Chemicals, Inc. Antithrombotic treatment with organic amine sulfites and bisulfites
US4400397A (en) * 1981-06-16 1983-08-23 T & R Chemicals, Inc. Antithrombotic treatment with quaternary ammonium sulfites and bisulfites
US4401654A (en) * 1980-06-30 1983-08-30 T & R Chemicals, Inc. Anticoagulant methods with sulfur dioxide
US4401655A (en) * 1981-06-16 1983-08-30 T & R Chemicals, Inc. Antithrombotic treatment with salts of sulfites and bisulfites
US4402946A (en) * 1981-06-16 1983-09-06 T & R Chemicals, Inc. Antithrombotic treatment
US4402982A (en) * 1982-01-05 1983-09-06 T & R Chemicals, Inc. Antihypertension treatment and composition therefor
US4402943A (en) * 1982-01-05 1983-09-06 T & R Chemicals, Inc. Antihypertension treatment
US4404202A (en) * 1982-01-05 1983-09-13 T & R Chemicals, Inc. Antihypertension treatment and composition therefor
US4555522A (en) * 1983-01-05 1985-11-26 T & R Chemicals, Inc. Antithrombotic and/or antihypertensive compositions

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327083A (en) * 1977-12-12 1982-04-27 T & R Chemicals, Inc. Treatment of hypertension with bisulfite
WO1982000097A1 (en) * 1980-06-30 1982-01-21 & R Chem Inc T The use of certain sulfites or bisulfites in compositions for treating thrombotic conditions
US4401654A (en) * 1980-06-30 1983-08-30 T & R Chemicals, Inc. Anticoagulant methods with sulfur dioxide
US4400396A (en) * 1981-06-16 1983-08-23 T & R Chemicals, Inc. Antithrombotic treatment with organic amine sulfites and bisulfites
US4400397A (en) * 1981-06-16 1983-08-23 T & R Chemicals, Inc. Antithrombotic treatment with quaternary ammonium sulfites and bisulfites
US4401655A (en) * 1981-06-16 1983-08-30 T & R Chemicals, Inc. Antithrombotic treatment with salts of sulfites and bisulfites
US4402946A (en) * 1981-06-16 1983-09-06 T & R Chemicals, Inc. Antithrombotic treatment
US4402982A (en) * 1982-01-05 1983-09-06 T & R Chemicals, Inc. Antihypertension treatment and composition therefor
US4402943A (en) * 1982-01-05 1983-09-06 T & R Chemicals, Inc. Antihypertension treatment
US4404202A (en) * 1982-01-05 1983-09-13 T & R Chemicals, Inc. Antihypertension treatment and composition therefor
US4555522A (en) * 1983-01-05 1985-11-26 T & R Chemicals, Inc. Antithrombotic and/or antihypertensive compositions

Similar Documents

Publication Publication Date Title
US3836639A (en) Use of aromatic glyoxals,their hydrates and bisulfite addition salts in reducing blood platelet aggregation
US3352754A (en) Therapeutic compositions comprising isoflavone compounds
US4118506A (en) Pharmaceutical compositions containing 1,3-dithiol-2-ylidene malonate derivatives
AU705447B2 (en) Eliminating agent for activated oxygen and free radicals
US5837706A (en) Drug for neuroprotection
JPS63270626A (en) Antiulcer agent
JPS6112622A (en) Hematopoietic stem cell differentiation and proliferation promoter
JPS60500769A (en) 2-acylimidazole compounds, their synthesis and use as drugs
US4237165A (en) Treatment of carbohydrate metabolism disorders
US3819830A (en) Method for treating diseases by coenzyme a and adenosine triphosphate and composition therefor
US4022907A (en) Pharmaceutical compositions containing 1,3-dithiacycloalkylidene malonates
US4153808A (en) Novel prostaglandin derivatives, certain in vivo and in vitro effects thereof and processes for the preparation of same
CA1211714A (en) Antithrombotic and/or antihypertensive compositions
US4080466A (en) Pharmaceutical compositions containing 4-hydroxyl-1,3-dithiolan-2-ylidene malonates
US5217990A (en) Use of macrolactones as anti-allergics
RU2039558C1 (en) Medicinal preparation possessing antiaggregate activity
US3840662A (en) Method of treating atherosclerosis using 4-hydroxymethyl-1-keto-1,2-dihydrophthalazine or acid salts thereof
US2899358A (en) Process
US4400396A (en) Antithrombotic treatment with organic amine sulfites and bisulfites
US4400397A (en) Antithrombotic treatment with quaternary ammonium sulfites and bisulfites
US4402946A (en) Antithrombotic treatment
EP0073345A2 (en) Sydnonimine derivatives, process for production thereof, and use thereof
EP0055996B1 (en) Antithrombotic treatment
CA1185529A (en) Antithrombotic treatment
US3663700A (en) Therapeutic hypotensive compositions comprising calcium salts of 5-alkylpicolinic acids